Search research articles
Contact Us
Filters
Showing results (41-50 of 123) with videos related to
Page
of 13
Sort By:
The Journal of Clinical Investigation
|
March 26, 2011
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
Tina Cascone, Matthew H Herynk, Li Xu, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
September 1, 2020
Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy
Erin M Corsini, Annikka Weissferdt, Apar Pataer, et al.
JAMA Oncology
|
March 21, 2024
Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis
Mark Sorin, Connor Prosty, Louis Ghaleb, et al.
Clinical Lung Cancer
|
February 25, 2020
Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients
Ravi Rajaram, Arlene M Correa, Ting Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Edward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials
Cesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2024
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, et al.
Journal for Immunotherapy of Cancer
|
July 8, 2026
Unbiased avidity-based isolation of antigen-specific T cells
Amanda Montoya, Meredith L Frank, Peixin Jiang, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2023
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
Antonio Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
Page
of 13
Search research articles
Search
Showing results (41-50 of 123) with videos related to
Sort By:
Page
of 13
The Journal of Clinical Investigation
|
March 26, 2011
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma
Tina Cascone, Matthew H Herynk, Li Xu, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
September 1, 2020
Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy
Erin M Corsini, Annikka Weissferdt, Apar Pataer, et al.
JAMA Oncology
|
March 21, 2024
Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis
Mark Sorin, Connor Prosty, Louis Ghaleb, et al.
Clinical Lung Cancer
|
February 25, 2020
Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients
Ravi Rajaram, Arlene M Correa, Ting Xu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Edward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
April 22, 2009
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials
Cesare Gridelli, Alessandro Morabito, Vittorio Gebbia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2024
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, et al.
Journal for Immunotherapy of Cancer
|
July 8, 2026
Unbiased avidity-based isolation of antigen-specific T cells
Amanda Montoya, Meredith L Frank, Peixin Jiang, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2023
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
Antonio Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
Page
of 13